The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EMN 2018 | Refining MRD analysis in myeloma: the role of PET-CT and MRI
Measurable residual disease (MRD) can be determined using a variety of techniques. However, the majority of trials perform bone marrow MRD evaluation, while few are determining the effectiveness of PET-CT and MRI. Here, Elena Zamagni, MD, PhD, from the University of Bologna, Bologna, Italy, explains some of the complications regarding interpreting patient MRD and how incorporating these imaging techniques could help reduce this ambiguity. This interview took place at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy.
